JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero maintains an Overweight rating on ACADIA Pharmaceuticals (ACAD) but lowers the price target from $29 to $25.

March 25, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on ACADIA Pharmaceuticals but lowers the price target from $29 to $25.
While the reduction in price target could suggest a tempered outlook on ACADIA Pharmaceuticals' short-term price potential, the maintenance of an Overweight rating by a major analyst like JP Morgan indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed positive rating.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100